arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Jazz Pharmaceuticals plc

JAZZ
$234.88 ▼ -5.68 (-2.36%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Jazz Pharmaceuticals plc faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $14.8B
Dividend Yield
Revenue Growth 15.5%
Op. Margin 20.5%
ROIC 2.1%
FCF / Share $6.29
Trailing P/E 77.0x
Price / Book 3.1x
FCF Yield 2.7%
Debt / Equity 0.91
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.21B
↑ +15.5%
Net Income Profit after all expenses
$293.10M
— 0.0%
Operating Margin Operating profit as % of sales
20.5%
↓ -34.8% 15th
FCF / Share Free cash flow per share
$6.29
— +0.2%
Long-Term Debt Long-term obligations
$4.35B
↓ -18.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
42
Returns
35
Financial Health
33
Cash Quality
4

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters